share_log

Texas Cannabis Company Secures $2B Valuation From LA Financial Firm

Texas Cannabis Company Secures $2B Valuation From LA Financial Firm

德克薩斯州大麻股公司獲得洛杉磯金融公司200億美元估值。
Benzinga ·  06/18 03:25

Cannabis Bioscience International Holdings (OTCPK: CBIH), a Texas-based cannabis company providing services for clinical research studies, announced Monday it received a $2 billion valuation following a rigorous assessment by StoneBridge Advisory, a Los Angeles financial advisory firm.

總部位於德克薩斯州的大麻生物科學國際控股(OTCPK:CBIH)爲臨床研究提供服務的大麻公司宣佈,經由洛杉磯財務諮詢公司StoneBridge Advisory的嚴格評估,其估值已達到20億美元。

Evaluation Supporting $2B Valuation

評估支持20億美元的估值

StoneBridge Advisory employed due diligence practices and financial modeling techniques to ensure the valuation's accuracy. This in-depth analysis involved a deep dive into CBIH's financial performance, its ability to capture market share, the competitive landscape it faces and its future plans. Additionally, the assessment took into account CBIH's team of experts, which combines expertise in legal and financial matters, creative design, scientific research and various medical fields. CBIH noted the 15 years of experience this team has, resulting in a range of innovative therapies that address gaps in traditional treatments and provide natural solutions for global health issues.

StoneBridge Advisory採用盡職調查實踐和財務建模技術以確保估值的準確性。這項深入的分析涉及大深度研究CBIH的財務表現、其獲取市場份額的能力、它所面臨的競爭格局以及未來的計劃。此外,該評估還考慮了CBIH的專家團隊,該團隊結合了法律和財務事務,創造性設計,科學研究和各種醫學領域的專業知識。CBIH指出,這個團隊有15年的經驗,產生了一系列創新療法,解決了傳統治療中存在的漏洞,併爲全球衛生問題提供了自然的解決方案。

CBIH's New Treasurer And Director Comment

CBIH的新財務主管和董事發表評論

John Jones, the recently named treasurer and director of CBIH, highlighted the company's strategic restructuring efforts. "We have been meticulously reconstructing our company and reinforcing its foundations. Given the promising opportunities we've identified, obtaining a valuation became the next logical step to gauge our progress and plan for future growth."

剛剛任命爲CBIH財務主管和董事的John Jones強調了公司的戰略重組努力。"我們一直在精心重構公司,加強其基礎設施。考慮到我們已經發現的有希望的機遇,獲得估值成爲衡量我們進展和規劃未來增長的下一個邏輯步驟。"

"Being positioned in rapidly evolving sectors like medical cannabis, clinical research, and biotechnology, coupled with our unparalleled expertise, positions us uniquely to seize advantageous opportunities that will benefit both our company and shareholders," Jones added.

"Jones補充道,作爲醫用大麻、臨床研究和生物技術等快速發展領域的重要位置,加上我們無與倫比的專業知識,使我們處於獨特的位置,能夠抓住優勢機遇,從而使我們的公司和股東都獲益。

Valuation Spurs Growth Plans

估值促使CBIH的增長計劃

This $2 billion valuation, which follows the company's public listing announced in December last year, places CBIH among the select group of companies that have surpassed that milestone. This achievement empowers CBIH to pursue strategic alliances, explore investment opportunities and embark on expansion plans.

這20億美元的估值跟隨公司去年12月宣佈上市,使CBIH成爲超過該里程碑的企業中的少數精選公司之一。這一成就使CBIH能夠追求戰略聯盟,探索投資機會並展開擴張計劃。

CBIH Price Action
CBIH's shares were trading at $0.0013 per share at the time of this writing around 11:30 AM ET Monday.

CBIH價格走勢
截至週一上午11:30左右,CBIH的股價爲每股0.0013美元。

Cannabis rescheduling seems to be right around the corner. Want to understand what this means for the future of the industry? Hear directly for top executives, investors and policymakers at the 19th Benzinga Cannabis Capital Conference, coming to Chicago this Oct. 8-9. Get your tickets now before prices surge by following this link.

大麻重新調度似乎就在眼前。想了解這對行業未來意味着什麼?10月8日至9日,來芝加哥參加第19屆Benzinga大麻資本大會,聽取高管、投資者和政策制定者的直接意見。立即購票,避免價格飆漲,請關注此鏈接.

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論